ATS 2018
Efficacy, Safety of Dupilumab in Corticosteroid-Dependent Severe Asthma
Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Your search for oral corticosteroids returned 13 results
ATS 2018
Lung Function in Severe Asthma Improved With Benralizumab
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
ATS 2020
Masitinib Significantly Reduced Exacerbations in Uncontrolled Severe Asthma
The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.
AES 2017
Effectiveness of Infantile Spasm Treatments Compared
Results found that infants with an unknown epilepsy etiology, a normal MRI, an EEG displaying hypsarrhythmia, or those already receiving an AED were more likely to be administered ACTH.
AAAAI/WAO 2018
Oral Glucocorticoid Use and Morbidities Examined in Pediatrics
Children with asthma who experience chronic oral glucocorticoid exposure may have significant morbidities, including adrenal suppression, recurrent pneumonia, and behavioral problems.
CHEST 2018
Inhaled Corticosteroid Therapy Refill Disruption Leads to Exacerbations
Disrupting regular combination inhaled corticosteroid therapy refills increased hospitalizations and exacerbations.
AAAAI 2017
Omalizumab Associated with Reduced Allergic Asthma Exacerbations, Hospitalizations
Omalizumab therapy was associated with reduced exacerbation and hospitalization rates in US clinics, according to findings from the prospective multicenter observational registry PROSPERO study
ATS 2020
COPD Maintenance Therapy: Adverse Outcomes With Tiotropium/Olodaterol vs LABA/ICS
In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.
AAAAI/WAO 2018
Reslizumab Efficacy Examined in Severe Eosinophilic Asthma
Reslizumab reduced the risk for exacerbations and improved lung function when compared to placebo, in patients with severe eosinophilic asthma.
AAAAI 2017
Is IL-5 Inhibition Effective in NSAIDs-Exacerbated Respiratory Disease?
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
